AU2018254884C1 - Blood purification through alkalifying agent - Google Patents

Blood purification through alkalifying agent Download PDF

Info

Publication number
AU2018254884C1
AU2018254884C1 AU2018254884A AU2018254884A AU2018254884C1 AU 2018254884 C1 AU2018254884 C1 AU 2018254884C1 AU 2018254884 A AU2018254884 A AU 2018254884A AU 2018254884 A AU2018254884 A AU 2018254884A AU 2018254884 C1 AU2018254884 C1 AU 2018254884C1
Authority
AU
Australia
Prior art keywords
pharmaceutical composition
alkalinizing agent
concentration
administration
urine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018254884A
Other languages
English (en)
Other versions
AU2018254884A1 (en
AU2018254884B2 (en
Inventor
Michiaki Abe
Kazuhiko Kawaguchi
Seizo Koshiba
Koichiro Nishioka
Yasuyuki Teranaka
Satomi Yamasaki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tohoku University NUC
Nippon Chemiphar Co Ltd
Original Assignee
Tohoku University NUC
Nippon Chemiphar Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP2017085741A external-priority patent/JP7578234B2/ja
Priority claimed from PCT/JP2017/032931 external-priority patent/WO2018193648A1/ja
Application filed by Tohoku University NUC, Nippon Chemiphar Co Ltd filed Critical Tohoku University NUC
Publication of AU2018254884A1 publication Critical patent/AU2018254884A1/en
Application granted granted Critical
Publication of AU2018254884B2 publication Critical patent/AU2018254884B2/en
Publication of AU2018254884C1 publication Critical patent/AU2018254884C1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2018254884A 2017-04-18 2018-03-13 Blood purification through alkalifying agent Active AU2018254884C1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
JP2017082423 2017-04-18
JP2017-082423 2017-04-18
JP2017-085741 2017-04-24
JP2017085741A JP7578234B2 (ja) 2017-04-18 2017-04-24 アルカリ性化剤による血液浄化
JP2017103935 2017-05-25
JP2017-103935 2017-05-25
AUPCT/JP2017/032931 2017-09-12
PCT/JP2017/032931 WO2018193648A1 (ja) 2017-04-18 2017-09-12 アルカリ性化剤による血液浄化
PCT/JP2018/009679 WO2018193752A1 (ja) 2017-04-18 2018-03-13 アルカリ性化剤による血液浄化

Publications (3)

Publication Number Publication Date
AU2018254884A1 AU2018254884A1 (en) 2019-11-07
AU2018254884B2 AU2018254884B2 (en) 2023-12-14
AU2018254884C1 true AU2018254884C1 (en) 2024-04-11

Family

ID=65033758

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018254884A Active AU2018254884C1 (en) 2017-04-18 2018-03-13 Blood purification through alkalifying agent

Country Status (8)

Country Link
US (1) US20210121426A1 (enExample)
EP (1) EP3616721B1 (enExample)
JP (3) JP7219898B2 (enExample)
KR (1) KR102685723B1 (enExample)
CN (1) CN110799214A (enExample)
AU (1) AU2018254884C1 (enExample)
CA (1) CA3060154A1 (enExample)
TW (1) TWI813560B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6792848B2 (ja) * 2018-05-25 2020-12-02 国立大学法人 琉球大学 代謝改善剤
US12324793B2 (en) 2018-10-17 2025-06-10 Tohoku University Method for renal protection
IL296692A (en) * 2020-03-26 2022-11-01 Univ Tohoku Renal function protective agent
CN114794346A (zh) * 2022-04-25 2022-07-29 武汉汇天诚科技有限公司 一种复合固体饮料的配方

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60105619A (ja) * 1983-11-15 1985-06-11 Nippon Chemiphar Co Ltd 尿アルカリ化性食品組成物
JP4087929B2 (ja) * 1997-08-27 2008-05-21 日清ペットフード株式会社 猫慢性腎不全治療用組成物及びその治療方法
JP2004131406A (ja) * 2002-10-09 2004-04-30 Sekisui Chem Co Ltd 尿毒症性物質特異的認識ポリマー及び経口吸着剤
CN105055446B (zh) * 2006-01-30 2022-06-03 宝龄富锦生技股份有限公司 逆转、防止、延迟或稳定软组织钙化的方法
JP2007217366A (ja) * 2006-02-17 2007-08-30 Kirin Brewery Co Ltd 尿酸値降下用組成物
WO2008141353A1 (en) * 2007-05-24 2008-11-27 Austin Health Prevention of acute kidney injury
RU2010112400A (ru) 2007-08-31 2011-10-10 Си.Би. ФЛИТ КОМПАНИ, ИНК. (US) Способ предупреждения нефрокальциноза
JP5197846B2 (ja) 2009-04-30 2013-05-15 紀陽 田仲 腎疾患重篤度を判定する方法又は装置若しくはその作動方法
JP6164719B2 (ja) * 2009-10-27 2017-07-19 エイワイファーマ株式会社 白金含有薬剤投与による腎障害の軽減剤
WO2012005240A1 (ja) * 2010-07-05 2012-01-12 株式会社明治 腸内腐敗物質の低減作用を有するビフィズス菌
MX357998B (es) * 2015-03-20 2018-07-11 Antonio Hernandez Miramontes Jorge Una mezcla de acidos carboxilicos, especificamente acido citrico, acido succinico, acido fumarico y acido malico para el tratamiento de pacientes con insuficiencia renal cronica, insuficiencia renal aguda, hepatopatias agudas o cronicas que cursen con hiperamonemia, enfermedades congenitas con alteraciones enzimaticas en el ciclo de la urea, asi como condiciones clínicas que cursen con balance nitrogenado negativo.
US12324793B2 (en) * 2018-10-17 2025-06-10 Tohoku University Method for renal protection
CN112912070A (zh) * 2018-10-17 2021-06-04 日本化学药品株式会社 夜间多尿的治疗或预防剂
JPWO2020222302A1 (enExample) * 2019-04-28 2020-11-05

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
ASHUTOSH MAHAJAN et al. KIDNEY INTERNATIONAL (2010) vol. 78, no. 3, pages 303-309 *
GADOLA LILIANA et al. KIDNEY INTERNATIONAL (2004) vol. 65, no. 4, pages 1224-1230 *
GEORGE A TANNER et al. J. AM. SOC. NEPHROL. (1998) vol. 9, pages 1242-1248 *
IONE DE BRITO-ASHURST et al. "Bicarbonate Supplementation Slows Progression of CKD and Improves Nutritional Status", JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2009) vol. 20, no. 9, pages 2075-2084 *
NIMRIT GORAYA et al. KIDNEY INTERNATIONAL (2012) vol. 81, no. 1, pages 86-93 *
Pernix Manufacturing "Material Safety Data Sheet Cytra-3 Syrup" Dated 4 September 2013. Retrieved from the internet on 8 May 2023 <URL: https://imgcdn.mckesson.com/CumulusWeb/Click_and_learn/MSDS_9CYPRS_CYTRA_3_SOL.pdf> *
SOROT PHISITKUL et al. "Amelioration of metabolic acidosis in patients with low GFR reduced kidney endothelin production and kidney injury, and better preserved GFR", KIDNEY INTERNATIONAL (2010) vol. 77, no. 7, pages 617 - 623 *
SOUMA, T. et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2011) vol. 22, no. 4, pages 635-648 *

Also Published As

Publication number Publication date
KR102685723B1 (ko) 2024-07-16
EP3616721A1 (en) 2020-03-04
TWI813560B (zh) 2023-09-01
EP3616721B1 (en) 2024-12-04
JP7219898B2 (ja) 2023-02-09
CA3060154A1 (en) 2018-10-25
EP3616721A4 (en) 2020-12-30
AU2018254884A1 (en) 2019-11-07
KR20190137147A (ko) 2019-12-10
JP7756863B2 (ja) 2025-10-21
EP3616721C0 (en) 2024-12-04
TW201838684A (zh) 2018-11-01
JP2023115271A (ja) 2023-08-18
JPWO2018193648A1 (ja) 2020-02-27
JPWO2018193752A1 (ja) 2020-03-05
US20210121426A1 (en) 2021-04-29
CN110799214A (zh) 2020-02-14
AU2018254884B2 (en) 2023-12-14

Similar Documents

Publication Publication Date Title
TWI847827B (zh) 利用鹼性化劑的血液淨化
AU2018254884C1 (en) Blood purification through alkalifying agent
JP5479318B2 (ja) アログリプチンおよび塩酸メトホルミンを含有する固形製剤
JP5284967B2 (ja) 打錠障害を生じない錠剤製剤
CN115087441A (zh) Sglt-2抑制剂用于预防和/或治疗猫科动物的心脏疾病的用途
WO2022036506A1 (zh) Sglt-2抑制剂与血管紧张素受体阻滞剂的组合物及用途
CN101966181A (zh) 包含坎地沙坦和氨氯地平的口服固体制剂及其新应用
AU2019361520A1 (en) Novel pharmaceutical composition
EP3868370A1 (en) Therapeutic or prophylactic agent for nocturia
Merschmann et al. Bioavailability of Magnesium and Potassium Salts Used as Potential Substitutes for Sodium Chloride in Human Nutrition—A Review
CN115315258A (zh) 肾功能保护剂
KR20170012169A (ko) 경구용 복합제제
EP3229841A1 (en) Veterinary composition comprising torasemide for the treatment of pulmonary edema associated with heart failure in domestic animals
US12048677B2 (en) Compositions and uses thereof for the treatment of heart failure in domestic animals
KR20210152943A (ko) 암로디핀, 로사르탄 및 클로르탈리돈을 단층정에 포함하는 심혈관계 질환의 예방 또는 치료용 약제학적 복합제제
JP2021024803A (ja) クエン酸第二鉄水和物を含む固形製剤
CN109069438A (zh) 包含β阻滞剂、转化酶抑制剂和抗高血压药或NSAID的药物组合物

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 18 DEC 2023

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 18 DEC 2023

FGA Letters patent sealed or granted (standard patent)